Arena Pharmaceuticals Inc

Arena Pharmaceuticals — Technical Presentation (July 2017)

13 slides from Arena Pharmaceuticals's technical presentation, Jul 10, 2017

  1. Slide 1: Ralinepag Phase 2 Clinical Results

    Ralinepag Phase 2 Clinical Results July 10, 2017 Exhibit 99.1

  2. Slide 2: Forward-Looking Statements

    Forward-Looking Statements This presentation includes forward-looking statements that involve a number of risks and uncertainties, including statements about our investigative stage drug candidate, ralinepag, including its potential to become best-in-class, profile and phase 3 and development planni

  3. Slide 3: Ralinepag Phase 2 Randomized, Placebo-Controlled Trial in WHO Group 1 PAH

    Ralinepag Phase 2 Randomized, Placebo-Controlled Trial in WHO Group 1 PAH 61 pts with PAH (2:1) - Evaluated efficacy, safety/tolerability and PK ~28 Day Screening Period 22-week Treatment Period Open-label Extension Study (APD811-007) or Exit Up to 9-Week Dose Titration Period 13-Week Treatment Peri

  4. Slide 4: Statistical Plan

    Statistical Plan PVR primary endpoint: Absolute change from baseline Primary efficacy analysis testing trial hypothesis Primary statistical test (2-sided, 0.05 alpha); subsequent testing without adjustment for multiplicity Log-transformation and geometric mean ratio (GMR) expressed as GMR percentage

  5. Slide 5: Baseline Characteristics

    Baseline Characteristics Placebo (n=21) Ralinepag (n=40) Mean Age, Years 55.6 46.2 Sex, n (%) Male Female 1 (4.8) 20 (95.2) 7 (17.5) 33 (82.5) Race, n (%) White Other 19 (90.5) 2 (9.5) 38 (95) 2 (5) Mean PVR, dyn·s·cm-5 598 780 Median PVR, dyn·s·cm-5 480 705 Mean 6MWD, m 351 393 WHO FC, % II III IV

  6. Slide 6: Distribution of Maintenance Dose

    Distribution of Maintenance Dose 57.5% of patients achieved a total daily dose of 200 mg or higher

  7. Slide 7: Ralinepag Significantly Improved Pulmonary Vascular Resistance (PVR); ITT Population

    1) Ralinepag Significantly Improved Pulmonary Vascular Resistance (PVR); ITT Population Primary Endpoint: Change in PVR Geometric Mean Ratio (GMR) [Expressed as Percent Change**] Treatment Effect Comparison -25.8% over placebo (p=0.02) *Median change used due to non-normal distribution; mean absolut

  8. Slide 8: Ralinepag Reduced PVR by 29.8% from Baseline Compared with Placebo

    2) Ralinepag Reduced PVR by 29.8% from Baseline Compared with Placebo; ITT Population Ralinepag (n=40) 9.6% -20.1% *Least squares mean change from placebo; non-parametric test to account for non-normal distribution -29.8% (P=0.03)* Placebo (n=21)

  9. Slide 9: Minute Walk Distance (6MWD)

    3) 6 Minute Walk Distance (6MWD) Ralinepag group increased by 36.2m from baseline (p=0.003) Placebo group increased by 29.4m from baseline (p=NS) Between group comparison directionally favors ralinepag (6.8m; p=NS) Clinically Meaningful Improvement for Ralinepag-Treated Patients

  10. Slide 10: Ralinepag Significantly Improved PVR and Increased 6MWD from Baseline

    Ralinepag Significantly Improved PVR and Increased 6MWD from Baseline 20.1% reduction in PVR* *PVR Least squares mean change; **6MWD = 6 minute walk distance – between group comparison not statistically significant 36.2m increase in 6MWD**

  11. Slide 11: Safety and Tolerability

    The overall safety and tolerability profile of ralinepag was consistent with the known profile of the prostacyclin therapy class Adverse events that occurred most frequently on ralinepag were similar to the on-target effects expected for prostacylin therapies: Headache, nausea, diarrhea, jaw pain, f

  12. Slide 12: Summary

    Summary Ralinepag Phase 2 trial results demonstrate meaningful efficacy among a contemporary PAH population Majority of patients receiving background dual combination therapy Ralinepag reduced median PVR by 163.9 dyn·s·cm-5 from a baseline of 705 dyn·s·cm-5 Statistically significant improvement over

  13. Slide 13: Focus on Pipeline

    Program Therapeutic Area/Indication PC P1 P2a P2b P3 Timing Ralinepag Potent IP Receptor Agonist Pulmonary Arterial Hypertension (PAH) P3 Preparations Etrasimod Optimized Activity S1P Receptor Modulator Ulcerative Colitis (UC) P2 Data by YE 2017 / Q1 2018 Extra-Intestinal Manifestations (EIM) in Irr

Arena Pharmaceuticals — Technical Presentation (July 2017) on 6ix